Ascendis Pharma A/S (BVMF:A1SN34)
Brazil · Delayed Price · Currency is BRL 86.76
0.00 (0.00%)
At close: Aug 28, 2026
Ascendis Pharma Revenue
Ascendis Pharma had revenue of 339.29M EUR in the quarter ending June 30, 2026, with 114.68% growth. This brings the company's revenue in the last twelve months to 1.05B, up 113.35% year-over-year. In the year 2025, Ascendis Pharma had annual revenue of 720.13M with 98.03% growth.
Revenue (ttm)
1.05B EUR
Revenue Growth
+113.35%
P/S Ratio
14.43
Revenue / Employee
880.59K EUR
Employees
1,189
Market Cap
89.45B BRL
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 720.13M | 356.49M | 98.03% |
| Dec 31, 2024 | 363.64M | 96.92M | 36.34% |
| Dec 31, 2023 | 266.72M | 215.54M | 421.20% |
| Dec 31, 2022 | 51.17M | 43.40M | 557.93% |
| Dec 31, 2021 | 7.78M | 825.00K | 11.87% |
| Dec 31, 2020 | 6.95M | -6.42M | -48.01% |
| Dec 31, 2019 | 13.38M | 2.79M | 26.41% |
| Dec 31, 2018 | 10.58M | 9.05M | 591.57% |
| Dec 31, 2017 | 1.53M | -3.08M | -66.78% |
| Dec 31, 2016 | 4.61M | -3.51M | -43.26% |
| Dec 31, 2015 | 8.12M | -5.87M | -41.94% |
| Dec 31, 2014 | 13.98M | -6.43M | -31.48% |
| Dec 31, 2013 | 20.41M | 4.83M | 30.96% |
| Dec 31, 2012 | 15.58M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Rede D'Or São Luiz | 57.79B |
| Raia Drogasil | 46.53B |
| Empreendimentos Pague Menos | 15.64B |
| Bradsaúde | 10.68B |
| Diagnósticos da América | 9.32B |
| Hypera | 8.82B |
| Fleury | 8.79B |
| Dimed S.A. Distribuidora de Medicamentos | 5.90B |
Ascendis Pharma News
- 19 hours ago - H.C. Wainwright trims Ascendis target, says litigation overhang removed - TheFly
- 19 hours ago - BioMarin price target raised to $60 from $59 at H.C. Wainwright - TheFly
- 20 hours ago - Ascendis Pharma Stock (ASND) Soars 7% on a Settlement with BioMarin Pharmaceutical (BMRN) - TipRanks
- 20 hours ago - Ascendis Pharma rises 8.0% - TheFly
- 20 hours ago - Ascendis Pharma price target lowered to $304 from $306 at BofA - TheFly
- 21 hours ago - Ascendis Pharma price target lowered to $330 from $333 at Jefferies - TheFly
- 22 hours ago - Ascendis Pharma price target lowered to $326 from $328 at Stifel - TheFly
- 23 hours ago - Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide) - GlobeNewsWire